The pipeline of products under review at FDA refilled in the past week after FDA's July 24 approvals jamboree, with submissions for products ranging from Merck & Co. Inc.'s problem-plagued anesthesia reversal agent to novel biologics for bleeding and immune disorders to new formulations of ADHD medications and the opioid overdose treatment naloxone.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?